This is a preview of subscription content, log in via an institution to check access.
Change history
12 October 2017
In the version of this article initially published, the first two sentences of paragraph 2, on p.809, column 2, incorrectly stated that MilliporeSigma had received patent grants for the proxy-CRISPR technology, whereas it has filed patent applications for this technology. The sentences, which follow, have been replaced: “It was a 'dead' version of Cas9 that secured patent rights for the life sciences arm of Merck KGA. The Darmstadt, Germany–based pharma's wholly owned subsidiary MilliporeSigma, received both European and Australian patents for its 'proxy-CRISPR' version of the genome editing system.” The business has received an Australian patent grant and a notice of intention from the European Patent Office for a patent that covers the integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR. In two instances in the same paragraph a “Merck” spokesperson should have been identified as being from “MilliporeSigma” and, similarly, “Merck claims” should have been “MilliporeSigma” claims. In addition, KGaA was misspelled as KGA; the third mention of “Neuman” was misspelled as “Newman.” The errors have been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. CRISPR patent estate splinters. Nat Biotechnol 35, 808–809 (2017). https://doi.org/10.1038/nbt0917-808b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0917-808b
- Springer Nature America, Inc.
This article is cited by
-
Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape
Journal of Industrial Microbiology and Biotechnology (2018)